You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
Johnson and Johnson
Dow
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-06648671

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PF-06648671?

PF-06648671 is an investigational drug.

There have been 4 clinical trials for PF-06648671. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2015.

The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are three US patents protecting this investigational drug and forty-nine international patents.

Recent Clinical Trials for PF-06648671
TitleSponsorPhase
An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.PfizerPhase 1
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)PfizerPhase 1
A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly SubjectsPfizerPhase 1

See all PF-06648671 clinical trials

Clinical Trial Summary for PF-06648671

Top disease conditions for PF-06648671
Top clinical trial sponsors for PF-06648671

See all PF-06648671 clinical trials

US Patents for PF-06648671

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06648671   Start Trial Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders Pfizer Inc. (New York, NY)   Start Trial
PF-06648671   Start Trial Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders Pfizer Inc. (New York, NY)   Start Trial
PF-06648671   Start Trial Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders PFIZER INC. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06648671

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06648671 Argentina 092628 2032-09-21   Start Trial
PF-06648671 Australia 2013319845 2032-09-21   Start Trial
PF-06648671 Brazil 112015006436 2032-09-21   Start Trial
PF-06648671 Canada 2882386 2032-09-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
Johnson and Johnson
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.